- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06526195
Proef om de veiligheid en effectiviteit van mechanische ondersteuning van de bloedsomloop te evalueren bij patiënten met voortschrijdend hartfalen (TEAM-HF)
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
Patients with heart failure (HF) suffer from a high degree of morbidity and mortality. Left ventricular assist device (LVAD) therapy has become the standard of care for the treatment of advanced HF patients who are deemed to be dependent on continuous intravenous inotropes, extending life expectancy, enhancing overall quality of life, and improving functional capacity. However, use of LVADs in ambulatory, non-inotrope dependent advanced HF population is limited. Elevated mean pulmonary artery pressure (PAP) secondary to left ventricular failure has emerged as a potential predictor of increased mortality risk for patients refractory to maximally tolerated guideline directed medical therapy (GDMT). In these patients, left ventricular failure with elevated mean PAP may represent objective criteria to identify advanced HF patients requiring heart replacement therapies such as LVAD.
The TEAM-HF IDE trial will enroll approximately 850 subjects with New York Heart Association (NYHA) Class IIIB/IV HF who had a prior heart failure hospitalization and an elevated mean PAP secondary to left ventricular failure. Elevated mean PAP will be identified using an implanted PAP monitoring sensor, the CardioMEMS PA Sensor. All subjects enrolled can have a previously implanted CardioMEMS PA Sensor or, if not, will be implanted with the CardioMEMS PA Sensor after enrollment. The overall objectives of TEAM-HF trial are two-fold: 1) To determine whether PAP can objectively identify patients most at risk for worsening HF and therefore most likely to benefit from earlier intervention with LVAD therapy and 2) To determine the benefit of LVAD therapy in non-inotrope advanced HF patients with elevated mean PAP refractory to GDMT.
The trial will include approximately 75 global sites and consists of a Randomized Arm and a Single Arm Registry.
The TEAM-HF Randomized Arm is a prospective, randomized, open-label study of the HeartMate 3 (HM3) left ventricular assist system (LVAS) versus continued GDMT in non-inotrope dependent HF patients. The objectives of the Randomized Arm are 1) To establish an objective disease-state criteria to trigger referral for a HM3 LVAS and 2) Demonstrate improvement in survival when non-inotrope dependent advanced HF patients are treated with the HM3 LVAS compared to being managed on medical therapy alone.
The TEAM-HF Single Arm Registry is a prospective, single-arm, open-label study of non-inotrope dependent HF patients who do not meet a mean PAP threshold after GDMT optimization. The objective of the Single Arm Registry is to characterize the progression of patients with non-inotrope dependent HF without elevated PAP.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Nourdine Chakouri, PhD
- Telefoonnummer: 925-989-5982
- E-mail: nourdine.chakouri@abbott.com
Studie Locaties
-
-
Copenhagen
-
Copenhagen, Copenhagen, Denemarken, 2100
- Werving
- Rigshospitalet
-
Contact:
- Christina Moeller
- Telefoonnummer: +00 453 545 6757
- E-mail: Christina.Moeller@regionh.dk
-
Hoofdonderzoeker:
- Kasper Rossing, MD
-
-
-
-
Saxon
-
Hanover, Saxon, Duitsland, 30625
- Werving
- Medizinische Hochschule Hannover
-
Hoofdonderzoeker:
- Dominik Berliner, MD
-
Contact:
- Antje Juergens
- Telefoonnummer: +49-0115-323-1113
- E-mail: juergens.antje@mh-hannover.de
-
-
Saxony
-
Leipzig, Saxony, Duitsland, 04289
- Werving
- Herzzentrum Leipzig GmbH
-
Hoofdonderzoeker:
- Michael Borger, MD
-
Contact:
- Victoria Himstedt
- Telefoonnummer: +49 341 865 25
- E-mail: victoria.himstedt@helios-health-institute.com
-
-
State of Berlin
-
Berlin, State of Berlin, Duitsland, 13353
- Werving
- Deutsches Herzzentrum der Charité
-
Hoofdonderzoeker:
- Felix Schoenrath, MD
-
Contact:
- Annegret Schneider
- Telefoonnummer: +49-304-593-2303
- E-mail: schneider@dhzb.de
-
-
-
-
Piedmont
-
Turin, Piedmont, Italië, 10126
- Werving
- A.O.U. Citta della Salute e della Scienza di Torino
-
Contact:
- Giuditta Cuccuru
- Telefoonnummer: +39 011 6335351
- E-mail: gcuccuru@cittadellasalute.to.it
-
Hoofdonderzoeker:
- Antonino Loforte, MD
-
-
-
-
Holland
-
Rotterdam, Holland, Nederland, 3015 CE
- Werving
- Erasmus MC - Thoraxcenter
-
Contact:
- Nico Van Den Berg
- Telefoonnummer: +31-010-703-9307
- E-mail: n.berg@erasmusmc.nl
-
Hoofdonderzoeker:
- Rudolf De Boer, MD
-
-
Utrecht
-
Utrecht, Utrecht, Nederland, 3584 CX
- Werving
- UMC Utrecht
-
Hoofdonderzoeker:
- Linda Van Laake, MD
-
Contact:
- Manon Kuikhoven
- Telefoonnummer: (088) 755-9432
- E-mail: m.j.kuikhoven@umcutrecht.nl
-
-
-
-
State of Vienna
-
Vienna, State of Vienna, Oostenrijk, 1090
- Werving
- AKH -Wien
-
Contact:
- Julia Riebandt, MD, PhD
- Telefoonnummer: +43 1 40400-69660
- E-mail: julia.riebandt@meduniwien.ac.at
-
Hoofdonderzoeker:
- Daniel Zimpfer, MD
-
-
-
-
Riyadh Region
-
Riyadh, Riyadh Region, Saoedi-Arabië, 11525
- Werving
- King Fahad Medical City
-
Hoofdonderzoeker:
- Mohammed Alreshidan, MD
-
Contact:
- Joud Hewaidi
- Telefoonnummer: +966-530003751
- E-mail: jhewaidi@kfmc.med.sa
-
Riyadh, Riyadh Region, Saoedi-Arabië, 12713
- Werving
- King Faisal Specialist Hospital
-
Contact:
- Luluah Altukhaifi
- Telefoonnummer: +966 0556481098
- E-mail: laltukaifi@kfshrc.edu.sa
-
Hoofdonderzoeker:
- Jehad Abdulhamid Al Buraiki, MD
-
-
-
-
CBohmia
-
Prague, CBohmia, Tsjechië, 14021
- Werving
- IKEM Prague
-
Hoofdonderzoeker:
- Ivan Netuka, MD
-
Contact:
- Telefoonnummer: +42 060 665 4220
- E-mail: martina.kucerova@ikem.cz
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85006
- Ingetrokken
- Banner-University Medical Center Phoenix
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72205
- Werving
- Baptist Health Medical Center
-
Hoofdonderzoeker:
- Patrick Campbell, MD
-
Contact:
- Victoria Marren
- Telefoonnummer: 678-654-0327
- E-mail: victoria.marren@baptist-health.org
-
-
California
-
Sacramento, California, Verenigde Staten, 95816
- Werving
- Sutter Medical Center
-
Contact:
- Jessica Mccall
- Telefoonnummer: 916-887-4654
- E-mail: jessica.mccall@sutterhealth.org
-
Hoofdonderzoeker:
- Michael Gibson, MD
-
San Francisco, California, Verenigde Staten, 94143
- Werving
- University of California at San Francisco
-
Contact:
- Tyre Richardson
- Telefoonnummer: (209) 650-5302
- E-mail: tyre.richardson@ucsf.edu
-
Hoofdonderzoeker:
- Shweta Motiwala, MD
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20010
- Werving
- Washington Hospital Center
-
Hoofdonderzoeker:
- Sheikh Farooq, MD
-
Contact:
- Hellina Birru
- Telefoonnummer: 202-877-6334
- E-mail: hellina.t.birru@medstar.net
-
-
Florida
-
Gainesville, Florida, Verenigde Staten, 32610
- Werving
- Shands at the University of Florida
-
Hoofdonderzoeker:
- Mustafa Ahmed, MD
-
Contact:
- Erikson Walter
- Telefoonnummer: 269-331-9581
- E-mail: erikson.walter@ufl.edu
-
Weston, Florida, Verenigde Staten, 33331
- Werving
- Cleveland Clinic Florida
-
Contact:
- Maria Mejia-Gomez
- Telefoonnummer: 954-659-5888
- E-mail: mejiagm@ccf.org
-
Hoofdonderzoeker:
- Mauricio Velez, MD
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30309
- Werving
- Piedmont Heart Institute
-
Hoofdonderzoeker:
- Catherine Marti, MD
-
Contact:
- Andrew Bailey
- Telefoonnummer: 404-605-4098
- E-mail: Andrew.Bailey1@piedmont.org
-
Augusta, Georgia, Verenigde Staten, 30901
- Werving
- Piedmont Augusta Hospital
-
Hoofdonderzoeker:
- Darshak Karia, MD
-
Contact:
- Jennifer Hansen
- Telefoonnummer: 706-724-2463
- E-mail: jennifer.hansen@piedmont.org
-
Marietta, Georgia, Verenigde Staten, 30060
- Werving
- WellStar Kennestone Hospital
-
Hoofdonderzoeker:
- Abdul Bikak, MD
-
Contact:
- Amuthanayaki Kanagaraj
- Telefoonnummer: 470-793-7554
- E-mail: amuthanayaki.kanagaraj2@wellstar.org
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- Werving
- University of Chicago
-
Contact:
- Kristen Hanauer
- Telefoonnummer: 773-702-8716
- E-mail: kristen.hanauer@bsd.uchicago.edu
-
Hoofdonderzoeker:
- Nikhil Narang, MD
-
Oakbrook Terrace, Illinois, Verenigde Staten, 60181
- Werving
- Advocate Health & Hospitals Corporation
-
Contact:
- Mairead Delaney
- Telefoonnummer: 708-684-4209
- E-mail: mairead.delaney@aah.org
-
Hoofdonderzoeker:
- Vinh Chau, MD
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46240
- Werving
- St. Vincent Hospital
-
Hoofdonderzoeker:
- Ashwin Ravichandran, MD
-
Contact:
- Regina Margiotti
- Telefoonnummer: 317-338-6151
- E-mail: Regina.Margiotti@ascension.org
-
-
Iowa
-
Iowa City, Iowa, Verenigde Staten, 52242
- Werving
- University of Iowa Hospitals & Clinics
-
Contact:
- Page Scovel
- Telefoonnummer: 319- 356-2585
- E-mail: Page-scovel@uiowa.edu
-
Hoofdonderzoeker:
- Anthony Panos, MD
-
-
Kansas
-
Kansas City, Kansas, Verenigde Staten, 66160
- Werving
- Kansas University Medical Center
-
Contact:
- Terry Christenson
- Telefoonnummer: 515-210-2626
- E-mail: tchristenson3@kumc.edu
-
Hoofdonderzoeker:
- Zubair Shah, MD
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40536
- Beëindigd
- University of Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40202
- Werving
- Norton Hospital
-
Contact:
- Laurie Michelle Jones
- Telefoonnummer: 502-891-8699
- E-mail: laurie.jones@nortonhealthcare.org
-
Hoofdonderzoeker:
- Alkhalil Bassel, MD
-
-
Maine
-
Portland, Maine, Verenigde Staten, 04102
- Werving
- Maine Medical Center
-
Contact:
- Monica Palmeri
- Telefoonnummer: 207-662-2090
- E-mail: monica.palmeri@mainehealth.org
-
Hoofdonderzoeker:
- Peter Kennel, MD
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Werving
- Massachusetts General Hospital
-
Contact:
- Bronwen Rees-Weidemann
- Telefoonnummer: 617-726-5508
- E-mail: brees-wiedemann@mgh.harvard.edu
-
Hoofdonderzoeker:
- Erin Coglianese, MD
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48202
- Werving
- Henry Ford Hospital
-
Contact:
- Zack Malouf
- Telefoonnummer: 313-585-7068
- E-mail: zmalouf1@hfhs.org
-
Hoofdonderzoeker:
- Lindsey Aurora, MD
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Werving
- Spectrum Health Butterworth Hospital
-
Contact:
- Stephanie Hanson
- Telefoonnummer: 616-391-0284
- E-mail: stephanie.hanson@corewellhealth.org
-
Hoofdonderzoeker:
- Matthew Gonzalez, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55407
- Werving
- Minneapolis Heart Institute
-
Hoofdonderzoeker:
- Mosi Bennett, MD
-
Contact:
- Kate Jappe
- Telefoonnummer: 612-863-7347
- E-mail: Kate.Jappe@allina.com
-
Rochester, Minnesota, Verenigde Staten, 55905
- Werving
- Mayo Clinic
-
Contact:
- Colleen Irlbeck
- Telefoonnummer: 507-266-6879
- E-mail: Irlbeck.Colleen@mayo.edu
-
Hoofdonderzoeker:
- Andrew Rosenbaum, MD
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64111
- Werving
- St. Luke's Hospital
-
Hoofdonderzoeker:
- Timothy Fendler, MD
-
Contact:
- Amanda Huffman
- Telefoonnummer: 816-932-0391
- E-mail: ahuffman@saint-lukes.org
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68198
- Werving
- University of Nebraska Medical Center
-
Contact:
- Ryan Ruskamp
- Telefoonnummer: 402-836-9779
- E-mail: ryan.ruskamp@unmc.edu
-
Hoofdonderzoeker:
- Adam Burdorf, DO
-
-
New Jersey
-
Hackensack, New Jersey, Verenigde Staten, 07601
- Werving
- Hackensack University Medical Center
-
Hoofdonderzoeker:
- Kanika Mody, MD
-
Contact:
- Manuel Castillo
- Telefoonnummer: 551-996-2136
- E-mail: Manuel.Castillo@hmhn.org
-
Newark, New Jersey, Verenigde Staten, 07112
- Werving
- Newark Beth Israel Medical Center
-
Hoofdonderzoeker:
- Igor Gosev, MD
-
Contact:
- Patel Bhargavi
- Telefoonnummer: 516-600-1487
- E-mail: bhargavi.patel2@rwjbh.org
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87102
- Werving
- New Mexico Heart Institute
-
Contact:
- Rebecca Jones
- Telefoonnummer: 505-843-2827
- E-mail: Rebecca.Jones@lovelace.com
-
Hoofdonderzoeker:
- Dana Booth, MD
-
-
New York
-
Manhasset, New York, Verenigde Staten, 11030
- Werving
- North Shore University Hospital
-
Contact:
- Salome Reddy
- Telefoonnummer: 516-600-1459
- E-mail: seliareddy@northwell.edu
-
Hoofdonderzoeker:
- Maria Avila, MD
-
New York, New York, Verenigde Staten, 10032
- Werving
- New York-Presbyterian/Columbia University Medical Center
-
Contact:
- Jessica Idumonyi
- Telefoonnummer: 212-305-1368
- E-mail: joi2102@cumc.columbia.edu
-
Hoofdonderzoeker:
- Dor Lotan, MD
-
Rochester, New York, Verenigde Staten, 14642
- Werving
- University of Rochester Medical Center
-
Contact:
- Lori Caufield
- Telefoonnummer: (585) 273-4956
- E-mail: lori_caufield@urmc.rochester.edu
-
Hoofdonderzoeker:
- Leway Chen, MD
-
The Bronx, New York, Verenigde Staten, 10467
- Werving
- Montefiore Medical Center - Moses Campus
-
Hoofdonderzoeker:
- Yogita Rochlani, MD
-
Contact:
- Sabrina Sicilia
- E-mail: ssicilia@montefiore.org
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27599
- Werving
- University of North Carolina at Chapel Hill
-
Contact:
- Hanna Mixon
- Telefoonnummer: (919) 962-4896
- E-mail: hanna_mixon@med.unc.edu
-
Hoofdonderzoeker:
- William Mostertz, MD
-
Charlotte, North Carolina, Verenigde Staten, 28203
- Werving
- Carolinas Medical Center
-
Contact:
- Dana Amaro
- Telefoonnummer: 704-355-4794
- E-mail: dana.amaro@atriumhealth.org
-
Hoofdonderzoeker:
- Joseph Mishkin, MD
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45219
- Werving
- Christ Hospital
-
Contact:
- Susanne Pasley
- Telefoonnummer: 513-585-1777
- E-mail: susanne.pasley@thechristhospital.com
-
Hoofdonderzoeker:
- Emani Sitaramesh, MD
-
Cleveland, Ohio, Verenigde Staten, 44195
- Werving
- The Cleveland Clinic Foundation
-
Contact:
- Barbara Gus
- Telefoonnummer: 216-445-6552
- E-mail: gusb@ccf.org
-
Hoofdonderzoeker:
- Michael Tong, MD
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73112
- Werving
- Integris Baptist Medical Center
-
Contact:
- Jill Bethany Fife
- Telefoonnummer: (405) 951-8607
- E-mail: bethany.fife@integrishealth.org
-
Hoofdonderzoeker:
- Luke Cunningham, MD
-
Tulsa, Oklahoma, Verenigde Staten, 74104
- Werving
- Oklahoma Heart Institute at Utica
-
Contact:
- Allyson O'Guin
- Telefoonnummer: (918) 574-9253
- E-mail: allyson.oguin@hillcrest.com
-
Hoofdonderzoeker:
- Luis David Meggo Quiroz, MD
-
Tulsa, Oklahoma, Verenigde Staten, 74136
- Werving
- Saint Francis Hospital
-
Hoofdonderzoeker:
- Douglas Ensley, MD
-
Contact:
- Riley Pritzlaff
- Telefoonnummer: 918-494-8500
- E-mail: rpritzlaff@saintfrancis.com
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- Werving
- Oregon Health & Science University
-
Hoofdonderzoeker:
- Johannes Steiner, MD
-
Contact:
- Ricardo Mendoza
- Telefoonnummer: (503) 494-9511
- E-mail: Mendozri@ohsu.edu
-
-
Pennsylvania
-
Abington, Pennsylvania, Verenigde Staten, 19001
- Werving
- Abington Memorial Hospital
-
Contact:
- Colleen Marchand
- Telefoonnummer: 215-481-4661
- E-mail: colleen.marchand@jefferson.edu
-
Hoofdonderzoeker:
- Alexander Shpilman, MD
-
Hershey, Pennsylvania, Verenigde Staten, 17033
- Werving
- Penn State Milton S. Hershey Medical Center
-
Hoofdonderzoeker:
- John Boehmer, MD
-
Contact:
- Amanda Donnangelo
- Telefoonnummer: 717-531-0850
- E-mail: adonnangelo@pennstatehealth.psu.edu
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- University of Pennsylvania
-
Contact:
- Emma Markley
- Telefoonnummer: 585-273-3760
- E-mail: Emma.markley@pennmedicine.upenn.edu
-
Hoofdonderzoeker:
- Himabindu Vidula, MD
-
Philadelphia, Pennsylvania, Verenigde Staten, 15213
- Werving
- University of Pittsburgh Medical Center (UPMC)
-
Hoofdonderzoeker:
- Gavin Hickey, MD
-
Contact:
- Abbey Sung
- Telefoonnummer: 412-648-6024
- E-mail: sunga3@upmc.edu
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15212
- Werving
- Allegheny General Hospital
-
Hoofdonderzoeker:
- Matthew Lander, MD
-
Contact:
- Laurie Machen
- Telefoonnummer: 412-359-6181
- E-mail: Laurie.MACHEN@ahn.org
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425
- Werving
- Medical University of South Carolina
-
Hoofdonderzoeker:
- Arman Kilic, MD
-
Contact:
- Melissa Lamicq
- Telefoonnummer: 954-683-4648
- E-mail: Lamicq@musc.edu
-
Columbia, South Carolina, Verenigde Staten, 29203
- Werving
- Prisma Health Midlands
-
Contact:
- Brooks Ferguson
- Telefoonnummer: 843-442-0994
- E-mail: Brooks.Ferguson@prismahealth.org
-
Hoofdonderzoeker:
- James Ampadu, MD
-
Contact:
- Abigail Anderson
- Telefoonnummer: 864-455-7629
- E-mail: Abigail.Anderson@prismahealth.org
-
-
Tennessee
-
Memphis, Tennessee, Verenigde Staten, 38120
- Werving
- The Stern Cardiovascular Foundation
-
Contact:
- Rishi Bhula
- Telefoonnummer: 901-271-2220
- E-mail: rishi.bhula@sterncardio.com
-
Hoofdonderzoeker:
- Todd Edwards, MD
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78705
- Werving
- Ascension Texas Cardiovascular
-
Contact:
- Jennifer Mcsorley
- Telefoonnummer: 702-427-2014
- E-mail: jennifer.mcsorley@ascension.org
-
Hoofdonderzoeker:
- Raymond Bietry, MD
-
Dallas, Texas, Verenigde Staten, 75246
- Werving
- Baylor University Hospital
-
Contact:
- Shelby Shull
- Telefoonnummer: 214-818-2587
- E-mail: Shelby.Shull@BSWHealth.org
-
Hoofdonderzoeker:
- Cesar Guerrero-Miranda, MD
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Houston Methodist
-
Contact:
- Mary Kelly
- Telefoonnummer: (346) 238-8240
- E-mail: makelly@houstonmethodist.org
-
Hoofdonderzoeker:
- Cindy Martin, MD
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- CHI St. Luke's Health Baylor College of Medicine Medical Center
-
Hoofdonderzoeker:
- Ajith Nair, MD
-
Contact:
- Wajeeha Abrar
- Telefoonnummer: (713) 798-5404
- E-mail: Wajeeha.Abrar@bcm.edu
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- UTHealth Memorial Hermann
-
Contact:
- Lawana Self
- Telefoonnummer: 713-486-6751
- E-mail: lawana.self@uth.tmc.edu
-
Hoofdonderzoeker:
- Nathan Sriram, MD
-
Plano, Texas, Verenigde Staten, 75093
- Werving
- The Heart Hospital Baylor Plano
-
Contact:
- Shelby McCoy
- Telefoonnummer: 469-814-3524
- E-mail: shelby.mccoy@bswhealth.org
-
Hoofdonderzoeker:
- Aasim Afzal, MD
-
Temple, Texas, Verenigde Staten, 76508
- Werving
- Scott & White Memorial Hospital
-
Contact:
- Rohini Bagewadi
- Telefoonnummer: 254-724-1083
- E-mail: rohini.bagewadi@bswhealth.org
-
Hoofdonderzoeker:
- Yevgeniy Khariton, MD
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84132
- Werving
- University of Utah Hospital
-
Hoofdonderzoeker:
- Craig Selzman, MD
-
Contact:
- Ashley Elmer
- Telefoonnummer: 801-585-6775
- E-mail: ashley.elmer@hsc.utah.edu
-
-
Virginia
-
Charlottesville, Virginia, Verenigde Staten, 22908
- Werving
- University of Virginia Medical Center
-
Contact:
- Tevin Jefferson
- Telefoonnummer: 434-982-1058
- E-mail: MFU3QX@uvahealth.org
-
Hoofdonderzoeker:
- Mirnela Byku, MD
-
Richmond, Virginia, Verenigde Staten, 23219
- Werving
- Virginia Commonwealth University
-
Hoofdonderzoeker:
- Keyur Shah, MD
-
Contact:
- Saige Dagenhart
- Telefoonnummer: 402-677-0237
- E-mail: Saige.Dagenhart@vcuhealth.org
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53215
- Werving
- Aurora Medical Group
-
Hoofdonderzoeker:
- Nasir Sulemanjee, MD
-
Contact:
- Don Lobacz
- Telefoonnummer: 414-649-3438
- E-mail: donald.lobacz@aah.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Subject has provided written informed consent by signing the study Informed Consent Form (ICF) prior to any clinical investigation-related procedure
- LVEF ≤30% and Cardiac Index ≤ 2.5 L/min/m²
- Limited functional status as demonstrated by 6MWT ≤ 350 m due to HF related reasons OR peak VO2 ≤ 14 mL/kg/min (or <50% of predicted peak VO2 value)
- NYHA Class IIIB or NYHA Class IV
- Subject has ≥ 1 Heart Failure Hospitalization in the last 12 months
- Subject is already implanted with a CardioMEMS PA Sensor OR willing to undergo a CardioMEMS PA Sensor implant
- Subject is willing and able to be implanted with the HM3 LVAS if randomized to HM3 Group
Randomization Criteria:
- Subject has been implanted with a CardioMEMS PA Sensor for at least 90 days.
- Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
- mean PAP ≥ 30 mmHg.
- The subject will not be randomized if they have any other factor that represents inordinate risk for either continued GDMT or LVAD implant.
Single Arm Registry Criteria:
- Subject has received a CardioMEMS PA Sensor implant following enrollment in the trial.
- Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
- mean PAP <30 mmHg
Exclusion Criteria:
-
Subject is < 18 years of age at the time of informed consent.
-
Dependent on IV inotrope in the last 30 days.
-
Contra-indications to HM3 LVAS or CardioMEMS HF system.
-
Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or restrictive cardiomyopathy.
-
Technical obstacles to LVAD or CardioMEMS implantation which pose an inordinately high surgical risk, in the judgment of the implanter.
-
Existence of ongoing MCS.
-
Presence of mechanical aortic valve that will not be either converted to a bioprosthesis or oversewn at the time of LVAD implant.
-
History of any solid organ transplant.
-
Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management.
-
Presence of an active, uncontrolled infection.
-
Complex congenital heart disease.
-
Currently Pregnant or capable of becoming Pregnant and Unwilling to Use Contraception with LVAD.
-
History of pulmonary embolism within 30 days prior to enrollment or history of recurrent (>1 episode) pulmonary embolism and/or deep vein thrombosis.
-
Planned VAD or Bi-VAD support prior to enrollment.
-
Presence of any one of the following risk factors for or indications of severe end organ dysfunction or failure:
- An INR ≥ 2.0 not due to anticoagulation therapy
- An eGFR < 30 mL/min/1.73 m2 and nonresponsive to diuretic therapy or receiving chronic dialysis.
- Biopsy proven liver cirrhosis.
- Need for chronic renal replacement therapy.
- History of severe chronic obstructive pulmonary disease (COPD) defined by Forced Expiratory Volume FEV1 < 30% predicted.
- History of cerebrovascular disease with significant (> 80%) uncorrected internal carotid stenosis.
- Significant peripheral vascular disease (PVD) accompanied by ischemic rest pain or extremity ulceration.
-
Any condition other than HF that could limit survival to less than 24 months.
-
Participation in any other clinical investigation with an active treatment arm that is likely to confound study results or affect the study outcome.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Randomized Arm - HM3 Group
Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the HM3 group will receive the device within 14 days of randomization. |
The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
Andere namen:
The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.
Andere namen:
Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
Andere namen:
|
|
Experimenteel: Randomized Arm - Control Group
Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the control group will continue their medical therapy per established heart failure guidelines. |
The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
Andere namen:
Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
Andere namen:
|
|
Experimenteel: Single Arm Registry
Patients who do not meet the mean PAP threshold (mean PAP <30 mmHg) and are enrolled in the single arm will continue their medical therapy per established heart failure guidelines. |
The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
Andere namen:
Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Survival at 2 years free of disabling stroke, reoperation to replace the device, or worsening HF requiring listing for urgent heart transplantation or mechanical circulatory support, enrollment into hospice, or dependence on IV inotropes
Tijdsspanne: 2 years
|
The powered primary endpoint will be analyzed at 2 years following the Com-Nougue method and will be compared between the HM3 Group (HM3 LVAD) and the Control Group (GDMT) within the Intention-to-treat (ITT) population. |
2 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Rate of Safety Outcomes at 1-year
Tijdsspanne: 1 year
|
The powered secondary endpoint of Rate of Safety Outcomes at 1-year will be evaluated within the Intention-to-treat (ITT) population against a pre-specified performance goal. Components consist of the following:
|
1 year
|
|
Survival at 2 years
Tijdsspanne: 2 years
|
The powered secondary endpoint of survival at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. |
2 years
|
|
Quality of life score assessed with the Kansas City Cardiomyopathy Questionnaire
Tijdsspanne: 2 years
|
The secondary endpoint of Quality-of-life score at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Quality of life at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. The KCCQ scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life. Improvement of KCCQ by at least 10 points is considered clinically significant. |
2 years
|
|
Six-minute walk distance
Tijdsspanne: 2 years
|
The secondary endpoint of six-minute walk distance at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of six-minute walk distance at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
Hospitalizations for HF and/or Urgent HF Visit
Tijdsspanne: 2 years
|
The secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
Days alive and outside of the hospital
Tijdsspanne: 2 years
|
The secondary endpoint of days alive and outside of the hospital at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of days alive and outside of the hospital at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
All-cause hospitalizations
Tijdsspanne: 2 years
|
The secondary endpoint of all-cause hospitalizations at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all-cause hospitalizations at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
All adverse events (including all strokes) regardless of severity
Tijdsspanne: 2 years
|
The secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Finkelstein-Schoenfeld Win Ratio
Tijdsspanne: 5 years
|
The Finkelstein-Schoenfeld Win Ratio will be explored at 5 years as an additional analysis with the following hierarchy:
The Finkelstein-Schoenfeld Win Ratio will be analyzed between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the Finkelstein-Schoenfeld Win Ratio will be descriptively analyzed between the Single Arm and both the HM3 Group and Control Group of the Randomized Arm separately. |
5 years
|
|
Survival free of urgent LVAD or transplant
Tijdsspanne: 5 years
|
This additional descriptive analysis at 5-years will be performed to evaluate the proportion of patients who are alive and free of device replacement or transplant in the HM3 Group compared to the Single Arm Registry (de novo implant or transplant) |
5 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Kelly O'Connell, PhD, Abbott
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ABT- CIP-10521
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .